B

Beam Therapeutics
D

BEAM

30.445
USD
-2.71
(-8.16%)
مغلق
حجم التداول
94,418
الربح لكل سهم
-5
العائد الربحي
-
P/E
-19
حجم السوق
2,521,017,314
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
الأخبار
المقالات

العنوان: Beam Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making adouble-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.